• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen is pleased to invite you to an upcoming webinar on March 30, 2026, at 15:00 GMT | 16:00 CET

Mar 30, 2026 | 2026, Events, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link or contact us at IR@philogen.com for further details.

Philogen is pleased to invite you to an upcoming webinar on November 20, 2025, at 15:00 GMT | 16:00 CET.

Nov 20, 2025 | 2025, Events, Investors, Past Events

During the session, our management team will provide an update on the latest scientific and financial results. To register, please click on the link in the description or contact usat IR@philogen.com for further details.

Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

Oct 1, 2025 | 2025, Events, Past Events, Scientific

Dr. Emanuele Puca will give an oral presentation entitled: “Antibody-cytokine Fusions for Cancer Therapy: Late-Stage Clinical Results” Dr. Roberto de Luca will give an oral presentation entitled: “Engineering Antibody-Cytokine Fusion Proteins (Immunocytokines) for...

Philogen to attend the Biopharma and Life Sciences Private Event in London (UK) on November 18, 2025

Aug 4, 2025 | 2025, Events, Investors

Prof. Dario Neri will participate to the event, which will convene a distinguished community of executives, investors and thought leaders in BioPharma and Life Sciences.

Philogen Management to hold a Webinar to provide an update on Nidlegy™ Marketing Authorization Application in Melanoma.

Jun 25, 2025 | 2025, Events, Investors, Past Events

The Webinar will take place on June 25 at 10:00 ET | 15:00 GMT | 16:00 CET. Please use this link to register to the event or contact us at ir@philogen.com

Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.

Jun 11, 2025 | 2025, Events, Investors, Past Events

Following last night’s announcement regarding OncoACP3, we are pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET. Please contact us at IR@philogen.com or follow the link to register to the...
« Older Entries
Next Entries »

Recent Posts

  • Philogen is pleased to invite you to an upcoming webinar on September 25, 2026, at 14:00 GMT | 15:00 CET.
  • Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2026 (Price sensitive)
  • The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2026 (Price sensitive) – Courtesy English Translation
  • Updated Phase III PIVOTAL Results for Nidlegy™ Published in the Journal of Clinical Oncology
  • Nidlegy™ Marketing Authorization Application Resubmitted to EMA

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it